COCONUT CREEK, Fla. – April 10, 2013 — Greyson International Inc. (OTC Pink: GYSN), developer of an innovative, patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced that Greyson is forming a subsidiary that will have a business plan which will target the multi-billion dollar pharmaceutical industry.
“Greyson’s management team has been diligently working to launch our new Greyson Biomedical subsidiary and commercialize Trilexon® Delivery System in potentially enormous medical end markets,” said Greyson International Inc. CEO Harvey Tauman. “After demonstrating efficacy in topical applications in OTC products, our goal is to license our patented technology to companies interested in improving efficacy of their existing products or creating altogether new products.
Greyson International’s patented Trilexon® technology (U.S. Patent 8,268,335) combines a cationic emulsifying agent, oil soluble liquid polymer and naturally occurring lactate buffer system to dramatically improve the topical delivery of active ingredients. Unlike normal delivery agents, the patented formulation effectively delivers active ingredients to the skin at a more desirable pH level to enhance delivery/efficacy.
“We believe there is a lot of potential for Trilexon® Delivery System within the biomedical industry,” added CEO Harvey Tauman. “With more durable and stable delivery of active ingredients, we see potential in prescription products that promote healing, restore damaged cells, and relieve topical pain, as well as topical OTC products like pain relievers, eczema treatment, anti-itch creams, burn relief products, or sunscreens etc. Our team is working diligently to prove these claims and launching the new subsidiary in the near future in order to generate significant long-term value for our shareholders.”
About Greyson International, Inc.
Greyson’s primary focus is on its recently patented Trilexon® delivery system that’s taking the multi-billion dollar cosmetics and OTC pharmaceuticals industries by storm. Based on this technology, the company’s patented Trilexon® foundation creates a fine surface that is insoluble in water, keeping it in place even after sweating or contact with water. Ingredients are released continuously over an extended period of time, ensuring that the skin receives treatment at a constant steady pace to give it a healthy and youthful look. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International. The company also holds an investment in Blake Oil and Gas Limited (“Blake”), a privately owned, Guernsey registered, Oil and Gas Company. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.
This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.
Greyson International Inc.
Harvey Tauman, 954-482-0497
Chief Executive Officer